About: The effect of inhaled and intranasal sodium cromoglyeate on symptoms of upper respiratory tract infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effect of inhaled and intranasal sodium cromoglyeate on symptoms of upper respiratory tract infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effect of inhaled and intranasal sodium cromoglyeate on symptoms of upper respiratory tract infections
Creator	Alestig, K Aberg, B Aberg, N
Source	PMC
abstract	Background A well established drug for the treatment of asthma and allergy, sodium cromoglycale, was found in open trials to be useful as a symptomalic treatment for upper respiratory tract infections. Objective To compare the efficacy of inhaled and intranasal sodium cromoglyeate and matching placebos on the symptoms of upper respiratory tract infections. Methods Adult subjects with symptoms of runny nose, throat pain, or cough for less than 24 h were recruited. They were treated for 7 days using a randomized, double‐blind, placebo‐controlled, group comparative design. The medication given was: sodium cromoglyeate dry powder 20mg per inhalation in spincaps; sodium cromoglycate aqueous nasal spray delivering 5.2mg per dose; or matching placebo as dry powder and nasal spray. One spincap and one spray per nostril were taken every 2h during waking hours on days 1 and 2 and then four times daily on days 3–7. Severity of nine symptoms (general malaise, body aches and pains, chills and shivering, snzeening, nasal running, nasal blocking, sore throat, cough and voice disturbance) was recorded twice daily by subjects on diary cards, using a scale of 0 (absent) to 3 (severe). Results The sludy was conducted between February and April 1993. One hundred and eighteen patients aged 21–63 years (mean 41 years) were included. Symptoms resolved faster (P < 0.001) and the severity in the last three days of treatment was significantly less in patients treated with sodium cromoglycate than with placebo (P < 0.05‐day 5; P < 0.01‐day 6; P < 0.001‐day 7). Side‐effects were local and mild and did not differ between the treatment groups. Conclusion Sodium cromoglyeate administered both by inhalation and intranasally is an effective treatment for the symptoms of upper respiratory tract infection. Its combined safety and efficacy would make it an acceptable form of treatment for these conditions.
has issue date	2006-04-27(xsd:dateTime)
bibo:doi	10.1111/j.1365-2222.1996.tb00642.x
bibo:pmid	8889259
has license	no-cc
sha1sum (hex)	4930321576ed90bada0ad02ba0f448378b3ba2c9
schema:url	https://doi.org/10.1111/j.1365-2222.1996.tb00642.x
resource representing a document's title	The effect of inhaled and intranasal sodium cromoglyeate on symptoms of upper respiratory tract infections
has PubMed Central identifier	PMC7164824
has PubMed identifier	8889259
schema:publication	Clin Exp Allergy
resource representing a document's body	covid:4930321576ed90bada0ad02ba0f448378b3ba2c9#body_text
is schema:about of	named entity 'ACHES' named entity 'THROAT PAIN' named entity 'TWICE DAILY' named entity 'NOSTRIL' named entity 'BACKGROUND' named entity 'TO COMPARE' named entity 'TREATED WITH' named entity 'USING' named entity 'SYMPTOM' named entity 'PATIENTS' named entity 'PLACEBO' named entity 'BODY' named entity 'GROUP' named entity 'EFFECTIVE' named entity 'EXPERIMENTAL' named entity 'P<0.05' named entity 'sore throat' named entity 'placebo' named entity 'treatment groups' named entity 'intranasally' named entity 'upper respiratory tract infection' named entity 'nasal spray' named entity 'asthma' named entity 'body aches' named entity 'drug trials' named entity 'cytotoxic' named entity 'anti-viral' named entity 'common cold' named entity 'ICAM-1' named entity 'inhaled bronchodilators' named entity 'allergic inflammation' named entity 'nasal decongestants' named entity 'down-regulates' named entity 'rhinitis' named entity 'symptom' named entity 'allergic disease' named entity 'allergic rhinitis' named entity 'adverse reaction' named entity 'sore throat' named entity 'allergic inflammation' named entity 'respiratory mucosa' named entity 'lactating' named entity 'serological' named entity 'allergy' named entity 'allergic rhinitis' named entity 'shivering' named entity 'bronchodilating' named entity 'safety profile' named entity 'sodium' named entity 'Lomudal' named entity 'sodium' named entity 'symptom' named entity 'sodium' named entity 'mast cells' named entity 'treatment groups' named entity 'interferon' named entity 'TNFa' named entity 'bronchodilating' named entity 'mucosa' named entity 'sodium' named entity 'antitussives' named entity 'informed consent' named entity 'sodium cromoglycate' named entity 'placebo group' named entity 'symptom' named entity 'sodium' named entity 'URTI' named entity 'URTI' named entity 'adverse events' named entity 'waking hours' named entity 'placebo group' named entity 'viruses' named entity 'systemic absorption' named entity 'acute disease' named entity 'antibiotics' named entity 'tumour necrosis factor' named entity 'lower respiratory tract' named entity 'sodium cromoglycate' named entity 'placebo group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software